Riociguat as a treatment regime for pulmonary arterial hypertension: a review

References

• Ezzati M, Lopez AD, Rodgers A, et al. Selected major risk factors and global and regional burden of disease. Lancet 2002;360:1347–60
   PubMed Web of Science ®Google Scholar
• Walker RW, McLarty DG, Kitange HM, et al. Stroke mortality in urban and rural Tanzania: adult morbidity and mortality project. Lancet 2000;355:1684–7
   PubMed Web of Science ®Google Scholar
• Reddy KS, Yusuf S. Emerging epidemic of cardiovascular disease in developing countries. Circulation 1998;97:596–601
   PubMed Web of Science ®Google Scholar
• Singh RB, Suh IL, Singh VP, et al. Hypertension and stroke in Asia: prevalence, control and strategies in developing countries for prevention. J Hum Hypertens 2000;14:749–63
   PubMed Web of Science ®Google Scholar
• Ashaye MO, Giles WH. Hypertension in blacks: a literature review. Ethen Dis 2003;13:456–62
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206–52
   PubMed Web of Science ®Google Scholar
• Goldstein LB, Bushnell CD, Adams RJ, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:517–84
   PubMed Web of Science ®Google Scholar
• Nishizaka MK, Pratt-Ubunama M, Zaman MA, et al. Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension. Am J Hypertens 2005;18:805–12
   PubMed Web of Science ®Google Scholar
• Henningsen NC, Ohlsson O, Mattiasson I, et al. Hypertension, levels of serum gamma glutamyl transpeptidase and degree of blood pressure control in middle-aged males. Acta Med Scand 1980;207:245–51
   PubMed Web of Science ®Google Scholar
• Dedier J, Stampfer MJ, Hankinson SE, et al. Nonnarcotic analgesic use and the risk of hypertension in US women. Hypertension 2002;40:604–8
   PubMed Web of Science ®Google Scholar
• Taneja I, Diedrich A, Black BK, et al. Modafinil elicits sympathomedullary activation. Hypertension 2005;45:612–18
   PubMed Web of Science ®Google Scholar
• Anderson GH, Blakeman N, Streeten DH. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens 1994;12:609–15
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206–52
   PubMed Web of Science ®Google Scholar
• Nelson M. Drug treatment of elevated blood pressure. Aust Prescr 2010;33:108–12
   Web of Science ®Google Scholar
• Giuseppe M. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34:2159–219
   PubMed Web of Science ®Google Scholar
• Klarenbach SW, McAlister FA, Johansen H, et al. Identification of factors driving differences in cost effectiveness of first-line pharmacological therapy for uncomplicated hypertension. Can J Cardiol 2010;26:e158–63
   PubMedGoogle Scholar
• National Institute Clinical Excellence. 1.5 Initiating and monitoring antihypertensive drug treatment, including blood pressure targets. GC127 Hypertension: clinical management of primary hypertension in adults. Retrieved 23 December 2011; 12–23
   Google Scholar
• McLaughlin V, Archer S, Badesch D, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association Developed in Collaboration With the American College of Chest Physicians; American Thoracic Society, Inc; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009;53:1573–619
   PubMed Web of Science ®Google Scholar
• Simonneau G, Galiè N, Rubin LJ. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43:5S–12
   PubMed Web of Science ®Google Scholar
• Pulmonary arterial hypertension. Genetics Home Reference. Available from: http://ghr.nlm.nih.gov/condition=pulmonaryarterialhypertension. [last accessed 28 Sep 2011]
   Google Scholar
• Kim N. Chronic thromboembolic pulmonary hypertension. Medscape 2012
   Google Scholar
• Mittendorf J, Weigand S, Alonso-Alija C, et al. Discovery of Riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. Chem Med Chem 2009:4:853–65
   Web of Science ®Google Scholar
• Ghofrani HA, D'Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013;369:319–29
   PubMed Web of Science ®Google Scholar
• Mittendorf J, Weigand S, Alonso-Alija C, et al. Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. Chem Med Chem 2009;4:853–65
   Web of Science ®Google Scholar
• Stasch JP, Evgenov OV. Soluble guanylate cyclase stimulators in pulmonary hypertension. Handb Exp Pharmacol 2013;218:279–313
   PubMedGoogle Scholar
• Ghofrani HA, Galiè N, Grimminger F, et al. PATENT-1 Study Group Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013;369:330–40
   PubMed Web of Science ®Google Scholar
• Grimminger F, Weimann G, Frey R. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J 2009;33:785–92
   PubMed Web of Science ®Google Scholar
• Stasch JP, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 2011;123:2263–73
   PubMed Web of Science ®Google Scholar
• Linder JU, Schultz JE. The class III adenylyl cyclases: multi-purpose signalling modules. Cell Signal 2003;15:1081–9
   PubMed Web of Science ®Google Scholar
• Linder JU. Substrate selection by class III adenylyl cyclases and guanylyl cyclases. IUBMB Life 2005;57:797–803
   PubMed Web of Science ®Google Scholar
• Linder JU. Class III adenylyl cyclases: molecular mechanisms of catalysis and regulation. Cell Mol Life Sci 2006;63:1736–51
   PubMed Web of Science ®Google Scholar
• Wu J, Bai J, Bao Q, Zhao F. Lineage-specific domain fusion in the evolution of purine nucleotide cyclases in cyanobacteria. J Mol Evol 2008;67:85–94
   PubMed Web of Science ®Google Scholar
• Kuhn M. Structure, regulation, and function of mammalian membrane guanylyl cyclase receptors, with a focus on guanylyl cyclase-A. Circ Res 2003;93:700–9
   PubMed Web of Science ®Google Scholar
• Denninger JW, Marletta MA. Guanylate cyclase and the NO/cGMP signaling pathway. Biochim Biophys Acta 1999;1411:334–50
   PubMed Web of Science ®Google Scholar
• Takahashi T. Pathophysiological significance of neuronal nitric oxide synthase in the gastrointestinal tract. J Gastroenterol 2003;38:421–30
   PubMed Web of Science ®Google Scholar
• Bredt DS. Endogenous nitric oxide synthesis: biological functions and pathophysiology. Free Radical Res 1999;31:577–96
   PubMed Web of Science ®Google Scholar
• Karow DS, Pan D, Davis JH, et al. Characterization of functional heme domains from soluble guanylate cyclase. Biochemistry 2005;44:16266–74
   PubMed Web of Science ®Google Scholar
• Iyer LM, Anantharaman V, Aravind L. Ancient conserved domains shared by animal soluble guanylyl cyclases and bacterial signaling proteins. BMC Genomics 2003;4:1–8
   PubMed Web of Science ®Google Scholar
• Zhao Y, Marletta MA. Localization of the heme binding region in soluble guanylate cyclase. Biochemistry 1997;36:15959–64
   PubMed Web of Science ®Google Scholar
• Wedel B, Harteneck C, Foerster J, et al. Functional domains of soluble guanylyl cyclase. J Biol Chem 1995;270:24871–5
   PubMed Web of Science ®Google Scholar
• Nioche P, Berka V, Vipond J, et al. Femtomolar sensitivity of a NO sensor from Clostridium botulinum. Science 2004;306:1550–3
   PubMed Web of Science ®Google Scholar
• Pellicena P, Karow DS, Boon EM, et al. Crystal structure of an oxygen binding heme domain related to soluble guanylate cyclases. Proc Natl Acad Sci 2004;101:12854–9
   PubMed Web of Science ®Google Scholar
• Ma X, Sayed N, Baskaran P, et al. PAS-mediated dimerization of soluble guanylyl cyclase revealed by signal transduction histidine kinase domain crystal structure. J Biol Chem 2008;283:1167–78
   PubMed Web of Science ®Google Scholar
• Jonathan AW, Emily RD, Meindert HL, et al. The crystal structure of the catalytic domain of a eukaryotic guanylate cyclase. BMC Struct Biol 2008;8:1–11
   PubMed Web of Science ®Google Scholar
• Cheung BH, Cohen M, Rogers C, et al. Experience-dependent modulation of C. elegans behavior by ambient oxygen. Curr Biol 2005;15:905–17
   PubMed Web of Science ®Google Scholar
• Gray J, Karow DS, Lu H, et al. Oxygen sensation and social feeding mediated by a C. elegans guanylate cyclase homologue. Nature 2004;430:317–22
   Google Scholar
• Tesmer JJ, Sunahara RK, Gilman AG, Sprang SR. Crystal structure of the catalytic domains of adenylyl cyclase in a complex with Gsα.GTPγS. Science 1997;278:1907–16
   PubMed Web of Science ®Google Scholar
• Tesmer JJ, Sunahara RK, Johnson RA, et al. Two-metal–ion catalysis in adenylyl cyclase. Science 1999;285:756–60
   PubMed Web of Science ®Google Scholar
• Mosby. Pharmacokinetics. In: Mitchell JR, Horning MG. eds. Mosby's dictionary of medicine, nursing, & health professions. Philadelphia, PA: Elsevier Health Sciences; 2006:199
   Google Scholar
• Grimminger F, Weimann G, Frey R, et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J 2009;33:785–92
   PubMed Web of Science ®Google Scholar
• Lees P, Cunningham FM, Elliott J. Principles of pharmacodynamics and their applications in veterinary pharmacology. J Vet Pharmacol Ther 2004;27:397–414
   PubMed Web of Science ®Google Scholar
• Frey RMück W, Unger S, Artmeier-Brandt U, et al. “Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers”. J Clin Pharmacol 2008;48:1400–10
   PubMed Web of Science ®Google Scholar
• Yoshina S, Tanaka A, Kuo SC. “Studies on heterocyclic compounds. XXXVI. Synthesis of furo[3,2-c]pyrazole derivatives. (4) Synthesis of 1, 3-diphenylfuro[3,2-c]pyrazole-5-carboxaldehyde and its derivatives (author's transl)”. Yakugaku Zasshi (in Japanese) 1978;98:272–9
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, D'Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013;369:319–29
   PubMed Web of Science ®Google Scholar
• Hossein-Ardeschir G, Nazzareno G, Friedrich G, et al.. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013;369:330–40
   PubMed Web of Science ®Google Scholar